Lumos Pharma, Inc. – NASDAQ:LUMO

Financial Health
0
1
2
3
4
5
6
7
8
9

Lumos Pharma stock price monthly change

+163.03%
month

Lumos Pharma stock price quarterly change

+163.03%
quarter

Lumos Pharma stock price yearly change

+48.63%
year

Lumos Pharma key metrics

Market Cap
37.53M
Enterprise value
N/A
P/E
-0.93
EV/Sales
-18.20
EV/EBITDA
0.91
Price/Sales
18.41
Price/Book
0.47
PEG ratio
0.56
EPS
-4.59
Revenue
1.52M
EBITDA
-39.42M
Income
-37.12M
Revenue Q/Q
-76.12%
Revenue Y/Y
-27.48%
Profit margin
-2039.53%
Oper. margin
-2103.74%
Gross margin
0%
EBIT margin
-2103.74%
EBITDA margin
-2584.98%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Lumos Pharma stock price history

Lumos Pharma stock forecast

Lumos Pharma financial statements

Lumos Pharma, Inc. (NASDAQ:LUMO): Profit margin
Jun 2023 527K -8.93M -1694.69%
Sep 2023 7K -8.3M -118571.43%
Dec 2023 826K -9.45M -1144.92%
Mar 2024 165K -10.44M -6327.88%
Lumos Pharma, Inc. (NASDAQ:LUMO): Analyst Estimates
Mar 2024 165K -10.44M -6327.88%
Sep 2025 1.17M -7.29M -619.95%
Oct 2025 223.38K -3.16M -1415.01%
Dec 2025 19.57M -2.99M -15.32%
  • Analysts Price target

  • Financials & Ratios estimates

Lumos Pharma, Inc. (NASDAQ:LUMO): Debt to assets
Jun 2023 56373000 12.71M 22.55%
Sep 2023 47751000 12.25M 25.67%
Dec 2023 40638000 13.33M 32.81%
Mar 2024 28078000 10.63M 37.89%
Lumos Pharma, Inc. (NASDAQ:LUMO): Cash Flow
Jun 2023 -6.68M 1.08M -574K
Sep 2023 -7.82M 5.95M -435K
Dec 2023 -7.39M 6.17M 742K
Mar 2024 -12.89M 1M -5K

Lumos Pharma alternative data

Lumos Pharma, Inc. (NASDAQ:LUMO): Employee count
Aug 2023 33
Sep 2023 32
Oct 2023 32
Nov 2023 32
Dec 2023 32
Jan 2024 32
Feb 2024 32
Mar 2024 33
Apr 2024 33
May 2024 33
Jun 2024 33
Jul 2024 33

Lumos Pharma other data

28.41% -1.35%
of LUMO is owned by hedge funds
2.37M -105.51K
shares is hold by hedge funds

Lumos Pharma, Inc. (NASDAQ:LUMO): Insider trades (number of shares)
Period Buy Sel
Sep 2022 4469 0
Nov 2022 4000 0
Feb 2023 0 439
Apr 2023 0 2214
Aug 2023 0 3407
Transaction Date Insider Security Shares Price per share Total value Source
Sale
MCKEW JOHN C. officer: Chief Sc.. Common Stock 3,407 $3.21 $10,919
Sale
MCKEW JOHN C. officer: Chief Sc.. Common Stock 2,214 $3.27 $7,240
Sale
MCKEW JOHN C. officer: Chief Sc.. Common Stock 439 $3.53 $1,550
Purchase
MCCRACKEN JOSEPH S director
Common Stock 4,000 $5.03 $20,120
Purchase
HAWKINS RICHARD J director, officer.. Common Stock 208 $8.8 $1,830
Purchase
HAWKINS RICHARD J director, officer.. Common Stock 2,214 $8.84 $19,572
Purchase
HAWKINS RICHARD J director, officer.. Common Stock 1,506 $8.75 $13,178
Purchase
HAWKINS RICHARD J director, officer.. Common Stock 541 $8.65 $4,680
Purchase
MCCRACKEN JOSEPH S director
Common Stock 3,170 $8.6 $27,262
Purchase
RAFFIN THOMAS A. director
Common Stock 1,150 $8.46 $9,729
Patent
Application
Filling date: 24 Jan 2022 Issue date: 12 May 2022
Application
Filling date: 21 Dec 2020 Issue date: 14 Oct 2021
Application
Filling date: 14 Feb 2019 Issue date: 4 Mar 2021
Grant
Filling date: 20 Sep 2018 Issue date: 26 Jan 2021
Grant
Filling date: 1 Sep 2015 Issue date: 3 Dec 2019
Grant
Filling date: 21 Aug 2018 Issue date: 13 Aug 2019
Thursday, 12 December 2024
globenewswire.com
Wednesday, 6 November 2024
globenewswire.com
Wednesday, 23 October 2024
prnewswire.com
prnewswire.com
businesswire.com
Wednesday, 25 September 2024
globenewswire.com
Thursday, 15 August 2024
globenewswire.com
Thursday, 1 August 2024
seekingalpha.com
globenewswire.com
Tuesday, 23 July 2024
globenewswire.com
Monday, 20 May 2024
globenewswire.com
Wednesday, 15 May 2024
seekingalpha.com
Tuesday, 14 May 2024
globenewswire.com
Thursday, 9 May 2024
GlobeNewsWire
Monday, 26 February 2024
GlobeNewsWire
Tuesday, 7 November 2023
Zacks Investment Research
Thursday, 7 September 2023
GlobeNewsWire
Wednesday, 9 August 2023
Seeking Alpha
Wednesday, 26 July 2023
GlobeNewsWire
Wednesday, 3 May 2023
Zacks Investment Research
Wednesday, 19 April 2023
GlobeNewsWire
Wednesday, 1 March 2023
Zacks Investment Research
Wednesday, 15 February 2023
GlobeNewsWire
Monday, 14 November 2022
Zacks Investment Research
Tuesday, 9 August 2022
Seeking Alpha
Zacks Investment Research
Monday, 16 May 2022
GlobeNewsWire
Tuesday, 10 May 2022
Seeking Alpha
Thursday, 10 March 2022
Seeking Alpha
Wednesday, 23 February 2022
GlobeNewsWire
  • When is Lumos Pharma's next earnings date?

    Unfortunately, Lumos Pharma's (LUMO) next earnings date is currently unknown.

  • Does Lumos Pharma pay dividends?

    No, Lumos Pharma does not pay dividends.

  • How much money does Lumos Pharma make?

    Lumos Pharma has a market capitalization of 37.53M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.67% to 2.05M US dollars.

  • What is Lumos Pharma's stock symbol?

    Lumos Pharma, Inc. is traded on the NASDAQ under the ticker symbol "LUMO".

  • What is Lumos Pharma's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Lumos Pharma?

    Shares of Lumos Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Lumos Pharma's key executives?

    Lumos Pharma's management team includes the following people:

    • Mr. Richard J. Hawkins Chief Executive Officer & Chairman(age: 76, pay: $1,270,000)
    • Dr. John C. McKew Ph.D. Chief Scientific Officer & Pres(age: 61, pay: $747,990)
    • Mr. Carl W. Langren Consultant(age: 70, pay: $717,990)
    • Mr. Bradley J. Powers J.D. Chief Compliance Officer & Gen. Counsel(age: 46, pay: $677,080)
  • How many employees does Lumos Pharma have?

    As Jul 2024, Lumos Pharma employs 33 workers.

  • When Lumos Pharma went public?

    Lumos Pharma, Inc. is publicly traded company for more then 13 years since IPO on 11 Nov 2011.

  • What is Lumos Pharma's official website?

    The official website for Lumos Pharma is lumos-pharma.com.

  • Where are Lumos Pharma's headquarters?

    Lumos Pharma is headquartered at 4200 Marathon Boulevard, Austin, TX.

  • How can i contact Lumos Pharma?

    Lumos Pharma's mailing address is 4200 Marathon Boulevard, Austin, TX and company can be reached via phone at +51 22152630.

Lumos Pharma company profile:

Lumos Pharma, Inc.

lumos-pharma.com
Exchange:

NASDAQ

Full time employees:

30

Industry:

Biotechnology

Sector:

Healthcare

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

4200 Marathon Boulevard
Austin, TX 78756

CIK: 0001126234
ISIN: US55028X1090
CUSIP: 55028X109